给小鼠同种移植肿瘤模型施用FAPI的摩尔剂量影响FAP靶向PET显像与治疗
研究在野生型4T1荷瘤小鼠中比较不同摩尔剂量[68Ga]Ga-FAPI-04的PET显像及不同摩尔剂量[177Lu]Lu-DOTAGA.(SA.FAPi)2的治疗效果,发现随FAPI摩尔剂量增加出现梯度阻断效应,显像与治疗结局随之变化;低摩尔剂量[68Ga]Ga-FAPI-04 PET有助于表征小鼠源性FAP表达。
要点
- 随FAPI摩尔剂量增加,[68Ga]Ga-FAPI-04 PET显像出现梯度阻断效应。
- 随FAPI摩尔剂量增加,[177Lu]Lu-DOTAGA.(SA.FAPi)2治疗出现梯度阻断效应及不同治疗结局。
- 低摩尔剂量[68Ga]Ga-FAPI-04 PET可在多种肿瘤模型中表征小鼠源性FAP表达。
核心结论
- [68Ga]Ga/[177Lu]Lu-FAPI中FAPI的摩尔剂量对小鼠同种移植肿瘤模型的FAP靶向显像与治疗有实质性影响。
- 在临床前应用中,使用放射性标记FAP配体进行FAP靶向显像与放疗时,需仔细考虑放射性示踪剂的摩尔剂量以获得更好的可靠性与可重复性。
研究设计与样本
- 研究为小鼠同种移植肿瘤模型的临床前实验,使用野生型4T1荷瘤小鼠。
- 向野生型4T1荷瘤小鼠施用不同摩尔剂量的[68Ga]Ga-FAPI-04后进行静态PET显像,并生成S型曲线分析标准摄取值(SUV)与施用FAPI-04摩尔剂量的相关性。
- 向4T1荷瘤小鼠注射放射性活度一致但含不同摩尔DOTAGA.(SA.FAPi)2的[177Lu]Lu-DOTAGA.(SA.FAPi)2以评估治疗效果。
- [68Ga]Ga-FAPI-04也应用于不同肿瘤模型进行PET/CT显像。
主要发现
- 在[68Ga]Ga-FAPI-04 PET显像中,随FAPI摩尔剂量增加观察到梯度阻断效应。
- 在[177Lu]Lu-DOTAGA.(SA.FAPi)2治疗中,随FAPI摩尔剂量增加观察到梯度阻断效应,并出现不同的显像与治疗结局。
- 低摩尔剂量[68Ga]Ga-FAPI-04 PET在多种肿瘤模型中显示出表征小鼠源性FAP表达的潜力。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Since fibroblast activation protein (FAP), one predominant biomarker of cancer associated fibroblasts (CAFs), is highly expressed in the tumor stroma of various epidermal-derived cancers, targeting FAP for tumor diagnosis and treatment has shown substantial potentials in both preclinical and clinical studies. However, in preclinical settings, tumor-bearing mice exhibit relatively low absolute FAP expression levels, leading to challenges in acquiring high-quality PET images using radiolabeled FAP ligands (FAPIs) with low molar activity, because of which a saturation effect in imaging is prone to happen. Moreover, how exactly the molar dose of FAPI administered to a mouse influences the targeted PET imaging and radiotherapy remains unclear now. Therefore, this study aims to investigate the impacts of the molar dose of the administered FAPI on FAP-targeted PET imaging and radiotherapy in mouse syngeneic tumor models. METHODS: [68Ga]Ga-FAPI-04 with various molar doses of FAPI-04 was administered to wild-type 4T1 tumor-bearing mice, followed by static PET imaging. Sigmoidal curves were generated to analyze the correlation between the standard uptake value (SUV) and the administered molar doses of FAPI-04. Similarly, [177Lu]Lu-DOTAGA.(SA.FAPi)2 with a consistent dose of radioactivity but containing different moles of DOTAGA.(SA.FAPi)2 were injected into 4T1 tumor-bearing mice to assess the therapeutic effect. [68Ga]Ga-FAPI-04 was also applied to different tumor models for PET/CT imaging. RESULTS: A gradient blocking effect was observed with increasing FAPI molar dose in [68Ga]Ga-FAPI-04 PET imaging and [177Lu]Lu-DOTAGA.(SA.FAPi)2 treatment, with various imaging and therapeutic outcomes. [68Ga]Ga-FAPI-04 PET exhibit potentials to characterize murine derived FAP expression with low molar dose of administered FAPI-04 using various tumor models. CONCLUSION: The molar dose of FAPI in [68Ga]Ga/[177Lu]Lu-FAPI had a substantial impact on FAP-targeted imaging and therapy in mouse syngeneic tumor models. To acquire enhanced reliability and reproducibility in preclinical situation, it is critical to carefully consider the molar dose of the radiotracer when applying radiolabeled FAP ligands to FAP-targeted imaging and radiotherapy.
引用
- Liu L, Shi Y, He S, et al. The molar dose of FAPI administered impacts on the FAP-targeted PET imaging and therapy in mouse syngeneic tumor models. Eur J Nucl Med Mol Imaging. 2025. PMID: 39797968. doi:10.1007/s00259-025-07071-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。